Kiyoshi Nagata

Kiyoshi Nagata

Auto-generated profile, based on publicly available information

Kiyoshi Nagata

Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
TSTakamitsu Sasaki
Takamitsu Sasaki
YSYu Sato
Yu Sato
TKTakeshi Kumagai
Takeshi Kumagai
Kouichi YoshinariKouichi Yoshinari
Kouichi Yoshinari
KNKiyoshi Nagata
Kiyoshi Nagata
Health foods have been widely sold and consumed in Japan. There has been an increase in reports of adverse effects in association with the expanding health food market. While health food-drug interactions are a particular concern from the viewpoint of safe and effective use of health foods, information regarding such interactions is limited owing to the lack of established methods to assess the effects of health food products on drug metabolism. We therefore developed cells that mimicked the activities of cytochrome P450 1A2 (CYP1A2), CYP2C9, CYP2C19, CYP2D6, and CYP3A4, which strongly contribute to drug metabolism in human hepatocytes, and established a system to assess the inhibitory activity of health foods toward P450-mediated metabolism. We simultaneously infected HepG2 cells with five P450-expressing adenoviruses (Ad-CYP1A2, Ad-CYP2C9, Ad-CYP2C19, Ad-CYP2D6, and Ad-CYP3A4) to mimic the activity levels of these P450s in human hepatocytes, and named them Ad-P450 cells. The activity levels of P450s in Ad-P450 cells and human hepatocytes were calculated via simultaneous liquid chromatography/tandem mass spectrometry analysis utilizing a P450 substrate cocktail. We established Ad-P450 cells mimicking the activity levels of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in human hepatocytes. We determined the Km values of P450 substrates and IC50 values of P450 inhibitors in Ad-P450 cells. These values were approximately equivalent to those obtained in previous studies. We investigated the inhibitory effects of 172 health foods that were recently in circulation in Japan on P450-mediated metabolism using Ad-P450 cells. Of the 172 health foods, five products (two products having dietary effects, one turmeric-based product, one collagen-based product, and one propolis-containing product) simultaneously inhibited the five P450s by more than 50%. Another 29 products were also confirmed to inhibit one or more P450s. We established a comprehensive assessment system to elucidate the effects of health foods on P450-mediated metabolism and identified the inhibitory activity of 34 of 172 health foods toward the drug-metabolizing P450s. Our results may provide useful information to predict health food-drug interactions.

1 May 1998 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
Kouichi YoshinariKouichi Yoshinari
Kouichi Yoshinari
KNK Nagata
K Nagata
MSM Shimada
M Shimada
YYY Yamazoe
Y Yamazoe
Carcinogenic arylamines such as N-hydroxy-2-acetylaminofluorene (N-OH-AAF) are metabolically activated by mammalian sulfotransferases to form N-hydroxyarylamine O-sulfates. We previously showed that rat ST1C1 efficiently mediate these activations. These reactions occur in liver cytosols of humans as well as rats. However, the enzyme responsible for N-OH-AAF activation has not been identified in humans. In the present study, a human cDNA (ST1C2) encoding a sulfotransferase showing a high similarity with ST1C1, has been isolated from a human fetal liver cDNA library and expressed using a bacterial expression system. A clear difference was observed in the pH optima for p-nitrophenol sulfation between ST1C2 and ST1C1 expressed in Escherichia coli. In addition, ST1C2 did not mediate 3'-phosphoadenosine-5'-phosphosulfate-dependent DNA binding of N-OH-AAF. These results suggest that human ST1C2 has a clear different substrate specificity, in spite of the structural similarity, with rat ST1C1.

1 January 2002 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
KNKiyoshi Nagata
Kiyoshi Nagata
YYYasushi Yamazoe
Yasushi Yamazoe
Recent advances in human gene analysis promoted by the human genome project have brought us a massive amount of information. These data can be seen and analyzed by personal computer through individual Web sites. As a result, the best use of bioinformatic is essential for recent molecular biology research. Genetic polymorphism of drug-metabolizing enzymes influences individual drug efficacy and safety through the alteration of pharmacokinetics and disposition of drugs. Considerable amounts of data have now accumulated as allelic differences of various drug metabolizing enzymes. Current understanding of genotype information on cytochrome P450 is hereby summarized, based on the Web site for their use in individual optimization of drug therapy.

29 July 2020 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
SSSawako Shindo
Sawako Shindo
Shih-Heng ChenShih-Heng Chen
Shih-Heng Chen
SSSaki Saito-Gotoh
Saki Saito-Gotoh
KYKosuke Yokobori
Kosuke Yokobori
HHHao Hu
Hao Hu
MNMasahiko Negishi
Masahiko Negishi
Background: Estrogen receptor α (ERα) has been suggested to regulate anti-inflammatory signaling in brain microglia, the only resident immune cells in the brain. ERα conserves the phosphorylation motif at Ser216 within the DNA binding domain. Previously, Ser216 was found to be phosphorylated in neutrophils infiltrating into the mouse uterus and to enable ERα to regulate migration. Given the implication of this phosphorylation in immune regulation, ERα was examined in mouse microglia to determine if Ser216 is phosphorylated and regulates microglia’s inflammation. It was found that Ser216 was constitutively phosphorylated in microglia and demonstrated that in the absence of phosphorylated ERα in ERα KI brains microglia inflamed, confirming that phosphorylation confers ERα with anti-inflammatory capability. ERα KI mice were obese and weakened motor ability. Methods: Mixed glia cells were prepared from brains of 2-days-old neonates and cultured to mature and isolate microglia. An antibody against an anti-phospho-S216 peptide of ERα (αP-S216) was used to detect phosphorylated ERα in double immunofluorescence staining with ERα antibodies and a microglia maker Iba-1 antibody. A knock-in (KI) mouse line bearing the phosphorylation-blocked ERα S216A mutation (ERα KI) was generated to examine inflammation-regulating functions of phosphorylated ERα in microglia. RT-PCR, antibody array, ELISA and FACS assays were employed to measure expressions of pro- or anti-inflammatory cytokines at their mRNA and protein levels. Rotarod tests were performed to examine motor connection ability. Results: Double immune staining of mixed glia cells showed that ERα is phosphorylated at Ser216 in microglia, but not astrocytes. Immunohistochemistry with an anti-Iba-1 antibody showed that microglia cells were swollen and shortened branches in the substantial nigra (SN) of ERα KI brains, indicating the spontaneous activation of microglia as observed with those of lipopolysaccharide (LPS)-treated ERα WT brains. Pro-inflammatory cytokines were up-regulated in the brain of ERα KI brains as well as cultured microglia, whereas anti-inflammatory cytokines were down-regulated. FACS analysis showed that the number of IL-6 producing and apoptotic microglia increased in those prepared from ERα KI brains. Times of ERα KI mice on rod were shortened in Rotarod tests. Conclusions: Blocking of Ser216 phosphorylation aggravated microglia activation and inflammation of mouse brain, thus confirming that phosphorylated ERα exerts anti-inflammatory functions. ERα KI mice enable us to further investigate the mechanism by which phosphorylated ERα regulates brain immunity and inflammation and brain diseases.

1 January 2012 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
TMTamihide Mtsunaga
Tamihide Mtsunaga
MMMasataka Maruyama
Masataka Maruyama
TMTsutomu Matsubara
Tsutomu Matsubara
KNKiyoshi Nagata
Kiyoshi Nagata
YYYasushi Yamazoe
Yasushi Yamazoe
SOShigeru Ohmori
Shigeru Ohmori
Human fetal liver (HFL) cells express major drug metabolic enzymes CYP3A4, CYP3A5 and CYP3A7. In the fetal hepatocytes, betamethasone and dexamethasone (DEX) markedly enhanced the expression levels of CYP3A4 and CYP3A7 mRNAs and slightly increased the expression level of CYP3A5 mRNA. Interestingly, a high correlation between the CYP3A induction ability and the intensity of anti-inflammatory effect was observed. Human glucocorticoid receptor (GR)-small interfering RNA clearly attenuated the expression level of GR mRNA, and diminished the DEX-stimulated CYP3A4, CYP3A5 and CYP3A7 expression in HFL cells. These findings indicate that GR mediates the induction of CYP3A4 and CYP3A7 expression in human fetal hepatocytes as well as the CYP3A5.

1 August 2004 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MSMiki Shimada
Miki Shimada
RTReiko Terazawa
Reiko Terazawa
YKYoshiteru Kamiyama
Yoshiteru Kamiyama
WHWataru Honma
Wataru Honma
KNKiyoshi Nagata
Kiyoshi Nagata
YYYasushi Yamazoe
Yasushi Yamazoe
Although catecholamine sulfation is higher in the kidney than in the liver of mice, no detectable amounts of previously reported sulfotransferases (STs) such as St1a, St1b, St1c, and St1e were expressed in mouse kidney cytosols. A new sulfotransferase (St1d1) cDNA was isolated from kidney cDNA library of BALB/c strain by reverse transcription-polymerase chain reaction (RTPCR) using information from expressed sequence tags (EST) database. The cDNA sequence resembled that of cDNA reported previously (AA238910) (Sakakibara et al., 1998) but differed in two amino acids, 206Q/K and 216Y/F, in the deduced amino acid sequence. The St1d1 expressed had unique substrate specificities for catecholamine derivatives, which preferred their deaminated metabolites rather than their parent amines. St1d1 showed the highest activity toward 3,4-dihydroxyphenylacetic acid (230.2 ± 2.69 nmol/mg/min) among the examined substrate. St1d1 protein was abundant in kidney, followed by liver, lung, and uterus. Furthermore, an addition of anti-St1d1 serum in the cytosolic reaction mixture resulted in complete inhibition of the sulfotransferase activity suggesting a major role of St1d1 on catecholamine sulfations. No human ST1D ortholog was detected at both mRNA and protein levels, although ST1A5 selectively catalyzing parent amine sulfation was detected in human kidney. These results indicate the functional basis of sulfation and the clear species difference on renal catecholamine metabolisms in mice and humans.